Aura Biosciences Expanded Access Policy

Aura Biosciences is focused on developing precision therapies for solid tumors that aim to preserve organ function. Our goal is to successfully advance and seek marketing approval for innovative cancer treatments, initially in ocular and urologic oncology.  We are currently conducting clinical trials to assess the safety and effectiveness of our first investigational drug candidate in human subjects.

Expanded Access, also known as Compassionate Use, refers to a pathway in which patients with serious or immediately life-threatening diseases or conditions may gain access to an investigational product outside the context of participation in clinical trials.

At this time, Aura Biosciences believes that participation in one of our clinical trials is the most appropriate way to access our investigational therapy for ocular and urologic cancers, and therefore our investigational therapies are not currently available under expanded access programs. You and your health care provider may learn more about our clinical trials by visiting www.clinicaltrials.gov and searching for Aura Biosciences.

If you are a health care provider who is interested in learning more about our investigational therapies, or a physician with questions about participation in one of our clinical trials, please submit a request to MedicalAffairs@aurabiosciences.com. The company will acknowledge questions as soon as possible, usually within 5 business days of receipt.

Aura Biosciences may revise this policy at any time.